Rare muscle disease start-up Dyne raises $50M series A

Founded and incubated by Atlas Venture, newly launched Dyne Therapeutics Inc. (Cambridge, Mass.) announced a $50 million series A round with which it intends to develop therapies that deliver oligonucleotides directly into muscle to treat rare diseases.

Forbion and MPM Capital invested alongside Atlas in the round (see “The Dynamics of Dyne”)...